Genocea Names Bakali as Board’s Executive Director

Xconomy Boston — 

Genocea Biosciences, a privately-held vaccine developer in Cambridge, MA, said it has added Staph Bakali to its board as executive director. Bakali was formerly the chief operating officer of ID Biomedical, a Vancouver, BC-based vaccine developer that was acquired by drug giant GlaxoSmithKline in 2005 for $1.4 billion. Genocea is working on a variety of vaccine projects, including one we wrote about in collaboration with Seattle-based PATH to prevent pneumococcal infections.